These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37819695)

  • 1. Renin Inhibition and the Long-Term Renal Function in Patients With Hypertensive Emergency: A Retrospective Cohort Study.
    Ueno M; Fujii W; Ono W; Murata H; Fujigaki Y; Shibata S
    Am J Hypertens; 2024 May; 37(6):407-414. PubMed ID: 37819695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.
    Abe M; Suzuki H; Okada K; Maruyama N; Inoshita A; Baba S; Takashima H; Soma M
    Heart Vessels; 2013 Jul; 28(4):442-52. PubMed ID: 22618635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term antihypertensive effects of aliskiren, a direct renin inhibitor, in chronic hemodialysis patients.
    Ishimitsu T; Ohta S; Ohno E; Takahashi T; Numabe A; Okamura A; Ohba S; Hashimoto A; Matsuoka H
    Ther Apher Dial; 2013 Oct; 17(5):524-31. PubMed ID: 24107281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of aliskiren on blood pressure and humoral factors in hypertensive hemodialysis patients previously on angiotensin II receptor antagonists.
    Ito T; Ishikawa E; Fujimoto N; Okubo S; Ito G; Ichikawa T; Nomura S; Ito M
    Clin Exp Hypertens; 2014; 36(7):497-502. PubMed ID: 24433061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level.
    Bokuda K; Morimoto S; Seki Y; Yatabe M; Watanabe D; Yatabe J; Ando T; Shimizu S; Itoh H; Ichihara A
    Hypertens Res; 2018 Jun; 41(6):435-443. PubMed ID: 29618841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aliskiren and valsartan combination therapy for the management of hypertension.
    Epstein BJ
    Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively.
    Stanton AV; Dicker P; O'Brien ET
    Am J Hypertens; 2009 Sep; 22(9):954-7. PubMed ID: 19556972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct renin inhibition: focus on aliskiren.
    Pool JL
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl B):21-33. PubMed ID: 17970614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial.
    Kwakernaak AJ; Roksnoer LC; Lambers Heerspink HJ; van den Berg-Garrelds I; Lochorn GA; van Embden Andres JH; Klijn MA; Kobori H; Danser AH; Laverman GD; Navis GJ
    PLoS One; 2017; 12(1):e0169258. PubMed ID: 28118402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.
    Morishita Y; Hanawa S; Chinda J; Iimura O; Tsunematsu S; Kusano E
    Hypertens Res; 2011 Mar; 34(3):308-13. PubMed ID: 21124333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversibility of the effects of aliskiren in the renal versus systemic circulation.
    Schneider MP; Janka R; Ziegler T; Raff U; Ritt M; Ott C; Veelken R; Uder M; Schmieder RE
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):258-64. PubMed ID: 22173856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
    Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
    Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.
    Sato A; Fukuda S
    Hypertens Res; 2013 Oct; 36(10):879-84. PubMed ID: 23864056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
    Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.
    Uzu T; Araki SI; Kashiwagi A; Haneda M; Koya D; Yokoyama H; Kida Y; Ikebuchi M; Nakamura T; Nishimura M; Takahara N; Obata T; Omichi N; Sakamoto K; Shingu R; Taki H; Nagai Y; Tokuda H; Kitada M; Misawa M; Nishiyama A; Kobori H; Maegawa H;
    PLoS One; 2016; 11(12):e0164936. PubMed ID: 28033332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma renin activity and aldosterone concentrations in hypertensive cats with and without azotemia and in response to treatment with amlodipine besylate.
    Jepson RE; Syme HM; Elliott J
    J Vet Intern Med; 2014; 28(1):144-53. PubMed ID: 24428319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aliskiren improves blood pressure control and prevents cardiac damage in high-risk hypertensive subjects.
    Mazza A; Montemurro D; Zuin M; Schiavon L; Zorzan S; Chondrogiannis S; Ferretti A; Ramazzina E; Rubello D
    Minerva Cardioangiol; 2013 Aug; 61(4):461-9. PubMed ID: 23846012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases.
    Rashikh A; Ahmad SJ; Pillai KK; Najmi AK
    J Pharm Pharmacol; 2012 Apr; 64(4):470-81. PubMed ID: 22420653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.